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Executive Summary 
 
The format for this third annual report of the Lancet Commission follows the same pattern 
as in 2015 in concentrating on the main recommendations, all of which are evidence based 
and have been most carefully considered in terms of their ability to reduce the current 
burden of liver disease in the UK 
and its financial cost. The working 
groups set up around the 
recommendations have 
concentrated this year on 
producing a set of the main metrics 
which will enable further charting 
of disease prevalence and 
consequences on an annual basis. 
They have also identified those 
areas where important data is not 
being obtained and which needs to 
be rectified. The initial ten 
recommendations have been 
reduced from ten to eight because 
of some overlap between them 
and an awareness that certain of 
the measures were common to 
both. These are shown in Panel 1. 
The recommendations are also in 
agreement with the ongoing 
thinking and action of the All Party Parliamentary Group on Liver Health with which, as 
described in the Introduction, we are increasingly liaising. 
 
Panel 1:  The 8 Recommendations 
 
R1:  Improving expertise & facilities in primary care to strengthen 
detection of early disease and its treatment, & screening of high-risk 
patients in the community. 
  
R2: Establishment of acute liver services in district general hospitals 
linked with 30 regional specialist centres for complex investigations & 
treatment, & increased provision of medical & nursing training in 
hepatology 
  
R3:  A national review of liver transplantation to ensure better access 
for patients to increase capacity 
  
R4: Specialist paediatric services & continuity of care in transition 
arrangements for children with liver disease reaching adult life. 
  
R5: Measures to reduce overall alcohol consumption in the country  
  
R6: Promotion of healthy lifestyles to reduce obesity & the burden of 
NAFLD 
  
R7: Eradication of chronic HCV infection from the country by 2030 & a 
major reduction in the burden of disease for hepatitis B. 
  
R8:  Increasing awareness of liver disease in the general population & 
within the NHS; work of liver patient support groups. 
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For many of the recommendations there is as yet little progress to report as shown by the 
metrics in terms of reducing disease burden although together with the efforts of other 
bodies and agencies, there is some movement in that direction. Thus, with 
Recommendation 1 the recently published guidelines by NICE on fatty liver disease and the 
diagnosis of cirrhosis, are likely to help considerably in improving clinical management at 
general practitioner and community level, giving guidance as they do on the best pathways 
to follow for the early identification and treatment of liver disease. Similarly for 
Recommendation 2, on the very necessary need to improve hospital services, we can point 
to the completion of a major review of hospital staffing and facilities for the care of the sick 
liver patient in hospital. These will inform further efforts to improve hepatological expertise 
and facilities within the DGHs and the desired networks with specialist centres.                              
 
    Figure 1: 
The updated version of the maps published in last year’s report illustrates the considerable 
variation in levels of current provision and will be of value in discussions on rationalisation 
and avoidance of duplication in provision of acute services being proposed. The maps also 
illustrate the need for greater provision of liver services in the deprived areas which have 
the highest rates of liver disease morbidity and mortality. The number of District General 
Hospitals (DGHs) that do not meet the criteria for an acute liver service, is unacceptable.  
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Figure 2: 
 
 
 
Recommendation 3 relating to the national strategic review of liver transplantation in the 
UK is proceeding, albeit rather slowly. This is because of the need, with the financial 
constraints facing the NHS at present, for the costs of this procedure to be properly 
considered along with agreement on work packages. The recommendation remains that 
additional centres are set up to correct the present geographical inequalities and increase 
the number of liver transplants carried out. Of note here during the past year is the Likely 
increase in the number of donor organs available as a result of new developments in organ 
perfusion which can return function to donor livers, particularly those obtained in by DCD 
donation (donation after cardiac death) that were previously considered too damaged for 
use. Furthermore, initial results of the introduction of presumed consent in Wales have 
shown a striking increase in the number of organs being donated over the first four months 
of its operation. 
 
Recommendation 4 highlights again the ever increasing population of adolescents with liver 
disease requiring supervision and care arising from the better results of treatment of infants 
and children including the use of liver transplantation. The measures needed are outlined 
with some encouraging pilot statistics. 
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Recommendations, 5, 6 and 7. Sadly these sections on the consequences of the lifestyle 
issues of excess alcohol consumption and obesity, as well as viral hepatitis, make depressing 
reading. The section on liver disease due to alcohol shows the increase in alcohol 
consumption and hospital admissions that was predicted to follow removal of the escalator 
tax in 2014. The necessary measures to reverse this are again set out in this section 
including further information on the value of the MUP policy. A recently published, 
nationally commissioned representative survey of over 3000 respondents in Northern 
Ireland(1) again showed that the MUP policy targeted those suffering the greatest harm 
from drinking and would significantly reduce alcohol attributable mortality.  Recent studies 
have also shown that the percentage of total alcohol consumed by the heavy drinkers has 
increased from 13% to 17% (see Table 6 later in this document). 
 
Similarly there is little encouragement to report for Recommendation 6 on the introduction 
of effective measures to reduce obesity rates for the 60% of the population who are now in 
the overweight category. The outcry from the medical profession and public alike on the 
watering down of the sugar tax proposal is some indication of the realisation of the harmful 
effects of obesity in causing diabetes and heart attacks, let alone liver disease and primary 
hepatocellular carcinoma. Surveillance programmes for primary hepatocellular carcinoma in 
patients with cirrhosis as well as those with fatty liver disease, are still not being 
implemented in the DGHs despite the continued increase in the number of such cases. The 
enormous cost of obesity both to patient health, to the NHS and to society in general, are 
highlighted in the section and in the Introduction. 
 
Recommendation 7 does portray a more hopeful note on the treatment of hepatitis C 
positive patients. The new drugs that have been introduced are proving in practice to be 
both efficacious and safe, with resulting high levels of viral clearance. Operational Delivery 
Networks are in place throughout England and the main issues relate to how many and 
which cases should be treated, with the limitation on total cost imposed by NHS England. 
The very high price of the medication imposed by manufacturers on the Western world 
remains difficult to justify. 
 
For Recommendation 8, which relates to increasing public awareness of health problems 
from liver disease, there is undoubtedly very much more activity in the media on lifestyle 
healthcare issues. Most importantly the Commission is able to report considerable ongoing 
success in meeting with Parliamentarians. Engaging their support is essential if the 
necessary legislation and regulation are to be finally approved by Parliament. National Liver 
Disease Profiles detailing disease prevalence and mortality have been produced for each of 
the 533 Parliamentary constituencies and show a 17-fold difference in the rates for the most 
deprived areas. 
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Introduction 
 
Am I being too much of an optimist in seeing a little light at the end of the tunnel for the 
efforts of the Lancet Commission to reduce unacceptable levels of morbidity and mortality 
from liver disease in the UK, which predominantly affects those still in working life and 
increasingly being seen in the young? Lifestyle issues of excess alcohol consumption, obesity 
and viral hepatitis responsible for the majority of liver illness in this country are increasingly 
being featured in the media. As yet, however, the long entrenched Government policies on 
alcohol and obesity, based on not wanting to increase the nanny state, remain in place and 
the all powerful lobbies of the food and drinks industry continue to have a major influence. 
The increasing demands on the NHS and the resulting financial pressures must be a strong 
argument for the introduction of measures that can significantly reduce the prevalence of 
disease. The health benefits and cost to the country from tackling smoking through 
regulation and taxation should be an encouragement to Parliament to follow similar 
initiatives for the other major lifestyle issues.  £2.1billion is spent each year on the 
treatment of liver disease. Hospital admissions and mortality rates are increasing again, as 
described in this third report of the Lancet Commission. Being largely preventable, this 
cannot be justified, nor can the figure of nearly 60% of police officers time being spent on 
alcohol related offenses.  Furthermore, according to the Treasury’s own figures, without the 
cuts and freezes in alcohol duty over the past few years, including those in the 2015 Budget, 
alcohol duty would have raised £770million more for the Government exchequer in 
2016/17. As a result of scrapping the duty escalator, Government finances will be £2.9billion 
worse off by 2017/18(2). The costs of obesity alone amount to £5.1billion a year for the NHS 
with 40,000 deaths linked to people being overweight or obese. There were 440,288 
admissions to hospitals in England in 2014-15 where obesity was the main reason for a 
person being admitted or was a secondary reason. 
 
This year’s Lancet follow-up report with its emphasis on metrics, gives many other examples 
of the cost to the country of not taking the necessary measures over lifestyle issues. Sadly, 
the introduction of a sugar tax, proposed in the Queen’s Speech to Parliament, is now being 
watered down particularly with respect to important limits on advertising junk food 
although proposals on sugary drinks remain. How effective will be the targets set on the 
food industry for reducing sugar content of foods?  Dame Sally Davies, Chief Medical Officer 
for England, has bravely reduced safe limits for alcohol consumption for both women and 
men, based on national and international evidence of the progressive increased risk of 
developing various cancers including the common ones of breast and colon.  
 
On a more optimistic note, the two important guidelines for the investigation and 
management of liver disease have been published by NICE and one by the British Society of 
Gastroenterology should help in the earlier detection and management of liver disease.  
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This year has also seen the appointment of Dr Jez Thompson as the jointly funded British 
Liver Trust and Royal College of General Practitioners Clinical Champion of Liver Disease. 
Already he is making an impact as will be evident in his contribution to this year’s report. 
Improving healthcare for liver patients in the District General Hospitals is also of vital 
importance, as highlighted by the adverse NCEPOD reports and the new data from a 
comprehensive national survey of staffing and hospital facilities. This should provide the 
basis for better and more equitable planning of services particularly in deprived areas with 
high incidence of liver disease.  Public Health England (PHE) launched in August a new tool 
to help local authorities prevent or reduce the impact of alcohol harm. Known as CLeaR and 
based on the success of the tobacco control CLeaR tool, it provides a framework for local 
partnerships to review local structures and alcohol services. In addition we are seeing 
Scotland moving forward again on introducing the minimum unit price for alcohol both 
Wales and Northern Ireland are pursuing major programmes based on strong Government 
support tackling the harms of liver disease. More information on the work going on in the 
devolved countries is considered in the relevant sections of this year’s report and in the 
general reviews. 
 
Encouraging also this year and following on a start in 2015, has been the successful and 
increasing dialogue with Parliamentarians on raising awareness of liver disease in 
Parliament. The work has been greatly helped by the 
involvement of a lobbying agency, Incisive Health, to 
whom we are very indebted for their ability in 
making contacts and in following them through. This 
work has been greatly aided by an unrestricted 
educational grant from Norgine to the Foundation 
for Liver Research.  Representatives of the Lancet 
Commission held sixteen one-to-one meetings with 
parliamentarians from both the Government and 
opposition parties. Amongst these were a number of 
high profile meetings with Lord Prior of Brampton 
(Parliamentary Under Secretary of State for Health), 
Heidi Alexander MP (then the Shadow Secretary of 
State for Health) and Dr Sarah Wollaston MP (Chair 
of the Health Select Committee).  In addition to 
raising awareness of liver disease with them, the 
House of Lords had a debate on the implementation of the Lancet Commission’s 
recommendations and multiple Parliamentary Questions have been tabled both in the 
Commons and the Lords, on topics related to liver disease. In addition to private meetings, 
the Lancet Commission partnered with the All Party Parliamentary Group (APPG) on Liver 
Health in holding two parliamentary briefing events – one in the House of Lords (October 
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2015), and another in the House of Commons (July 2016). Both events sought to raise 
parliamentary awareness of the Lancet Commission’s blueprint for improvement and of the 
need to act to address the continuing liver disease crisis. Together these events were 
attended by 38 parliamentarians. In addition, we have been liaising closely with the Children 
of Alcoholics APPG which is being led by Liam Byrne, MP. 
 
July 2016 saw the launch of the Lancet Commission’s most recent campaigning resource, 
Constituency Liver Disease Profiles, designed to bring to life the health and financial impact 
of liver disease on local communities and generate greater interest in liver disease amongst 
MPs. As well as the National Liver Disease profiles (shown in Figure 1) part of this initiative 
has been to produce a customised infographic for each of the 533 parliamentary 
constituencies in England, bringing together exclusive data provided by Public Health 
England and existing data intelligence to provide a concise summary of the impact of liver 
disease on local populations. The data collected as part of this exercise has been used in 
targeting MPs from the fifty areas with the highest burden of liver disease. The remarkable 
17-fold difference between the burden of liver disease in the North West and rates in the 
Home Counties (Table 1) is a telling statistic and with its association with social deprivation 
shows also the need for wider social and public health measures in addition to reducing 
alcohol consumption and obesity. 
 
The Constituency Liver Disease Profiles are publically accessible on the Foundation for Liver 
Research website(3) and available to the wider liver disease community to be used in the 
briefing of relevant political stakeholders on the burden of liver disease in their areas.    
 
Going forward into 2017, the Commission will continue its engagement with 
Parliamentarians and it will explore other ways to communicate the burden of liver disease 
to key stakeholders, such as healthcare commissioners, local authorities and those charged 
with developing and implementing sustainability and transformation plans.  
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Recommendation 1: Improving expertise and facilities in primary care to 
strengthen detection of early disease and its treatment, and screening of 
high-risk patients in the community 
 
 
Panel 2:   Metrics for Recommendation 1 
 
1.1  Percentage of adult patients in primary care who have had BMI 
recorded in the preceding year 
1.2  Percentage of adult patients in primary care who have had a measure of 
alcohol consumption or risk in the preceding year 
1.3  Percentage of adult injecting drug users who have had a recent HCV test  
1.4  Percentage of adult injecting drug users who have had HBV 
immunisation  
1.5  Introduction of a suite of Read Codes to cover liver disease risk factors, 
diagnoses and interventions to facilitate excellence of clinical care and 
practice audit and performance monitoring 
1.6  To ensure that all children born at term in the UK with conjugated 
jaundice are referred to a National Paediatric Liver Unit before they are 
8 weeks old. 
 
 
• The most common forms of liver disease have risk factors which are shared with 
other co-morbidities typically already under primary care surveillance, and which can 
be identified and addressed within primary care to prevent liver pathology 
developing.  
 
• Once developed, liver disease is typically slow to progress, and the patient with early 
disease may remain asymptomatic for years, while the disease itself is slowly 
advancing in severity. Early intervention, risk modification and treatment within 
primary care may prevent or retard progression to cirrhosis and end stage liver 
disease.  
 
• Patients with advanced liver disease spend the majority of their lives within their 
own families and communities where they are registered with a GP. Though many 
with advanced liver disease attend secondary care outpatient clinics and some have 
repeated hospital admissions during acute crises, much of their healthcare is 
provided within community settings. 
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For these reasons clinicians working in primary care and other community services, 
including community drug services, have unique and important roles in the prevention, early 
detection and management of liver disease. Engagement will reflect local factors, including 
local prevalence, population demographics and level of prioritisation by local 
commissioners, as well as mechanisms to incentivise staff and investment in support 
services. Focusing on the key liver conditions, these roles and potential roles are: 
 
• Primary prevention of liver disease. This includes screening for hazardous and 
harmful alcohol use and obesity(4) and having access to early in-house interventions 
or referral pathways to services to address these issues(5, 6). Hepatitis B 
immunisation for those at risk, including injecting drug users, is another form of 
primary prevention. Critical to primary care, and to pressing workload 
considerations, is the recognition that many risk factors for liver disease are also risk 
factors for other long-term conditions. Effective screening for liver disease risk 
factors does not necessarily mean ‘new work’, rather the linking of liver disease to 
current best practise and the monitoring and management of other conditions. 
 
• Secondary prevention of liver disease. This includes screening for hepatitis C(7, 8) 
and hepatitis B infections in those who have been in the past, or are current, drug 
injectors or who have other risk factors(9), and onward referral if necessary(5). It 
also includes case-finding for early liver disease in those with high-risk obesity or 
alcohol use and providing appropriate interventions and ongoing monitoring(6, 10). 
 
• Tertiary prevention of the consequences of established and more severe liver 
disease. This includes ongoing involvement in the support, monitoring and 
management of patients with more advanced liver disease, together with 
appropriate referral of patients to secondary care services(11). Further 
developments may include appropriately resourced and supported initiatives to 
move areas of care traditionally delivered within secondary care to primary care, 
such as hepatitis C treatment, building on innovative models and frameworks 
already in place(12-14).  
 
 
Substantial work has already been done to raise the profile of these roles for primary care 
practitioners. The Lancet Commission publications have provided several recommendations 
with unique relevance to primary care(11, 15). In 2016 the Royal College of General 
Practitioners selected liver disease as a one of their Clinical Priority programmes(16) and, in 
partnership with the British Liver Trust, has recently appointed a primary care Clinical 
Champion for Liver Disease(17). This builds in part on the RCGP Nutrition for Health clinical 
priority programme (2011-2015), whose RCGP Nutrition Position Statement clarified the 
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need for greater primary care action on obesity and the role of obesity as a risk factor for 
liver disease(18). An RCGP Liver Disease position statement will be developed as part of this 
new Clinical Priority programme, in order to benchmark good practice in primary care, and 
to support the translation of new NICE NAFLD and Cirrhosis Guidance into service delivery, 
especially where investment in commissioning new diagnostic testing facilities is required.   
 
Raising the profile of liver disease within primary care requires the development of robust 
guidance together with effective drivers to alter clinical practice(15). These include 
professional training, development of toolkits and pathways, and investment in services to 
facilitate increased management of liver conditions within primary care(15). Bold 
investment plus innovative local commissioning initiatives will be needed if traditional areas 
of secondary care management, such as hepatitis C treatment, are to feature more in 
primary care as the price of the next two antiviral agents falls and current arrangements 
through the Operational Delivery Networks (ODNs) are less necessary. Innovations require a 
full and realistic awareness of the large number of patients at risk of and with early liver 
disease, and the multiple competing workload pressures that already exist within primary 
care(11). 
 
As part of moving forwards with the Lancet Commission recommendations, a number of 
metrics have been proposed, to assess where we are now, and to guide future 
developments. The metrics agreed to support the Lancet Commission’s Recommendation 1 
are given in Panel 1. 
 
Metric 1: Percentage of adult patients in primary care who have had BMI recorded in the 
preceding year 
 
Non-alcoholic fatty liver disease (NAFLD) is an increasingly important cause of liver disease 
including cirrhosis as obesity rates rise at all ages within the UK, and for this reason 
assessing the percentage of adult patients in primary care who have had their BMI recorded 
in the preceding year is important(19). Primary care is uniquely placed to identify obesity 
and measuring and recording the BMI of a patient in the obese range is the first stage to 
providing in-house interventions or accessing a local tiered weight management pathway.  
Despite IT developments within primary care, full data on BMI recording in general practice 
are not easily accessible. The data are held neither at the level of the CCG or devolved 
nation equivalent, nor by the relevant national public health body for the four nations of the 
UK. Complete data sets are available at practice level, but to access them would require 
large-scale surveys of practices across the UK.  
 
The literature suggests that GPs are not comfortable addressing obesity as a health issue. 
Ogden and Flanagan found that GPs are ambivalent about the effectiveness of obesity 
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interventions, finding that ‘obesity does not belong within the medical domain’(20, 21). In 
2004 Hankey et al found that less than 10% of GPs had carried out any form of audit to 
determine the prevalence of overweight or obesity in their practice population, and that 
health professionals were generally unclear on how to deliver effective weight management 
advice(22).  Other published evidence points to GPs’ concern about the potential for 
damaging their relationship with their patients by bringing up the thorny issue of 
obesity(23). More recent work has reiterated concerns about barriers to case finding and 
obesity management in primary care which centre on uncertainty about the evidence base, 
while signposting to useful resources to address sensitivities about raising the topic of 
obesity in consultations and other training resources(24). 
 
The best data for this metric come from the financial incentive QOF target and payment 
scheme for GPs. One QOF target has been the establishment and maintenance of a register 
of patients aged 16 and over with a recorded BMI ≥30 in the preceding 12 months. QOF 
recorded prevalence for obesity in England in 2014/15 was 9%, representing 4.2 million 
patients, and obesity was the second highest recorded disease prevalence after 
hypertension(25). In Scotland the figure was 8% in 2014/15(26), and Wales 2014/15 9.5% 
(27). Northern Ireland data do not include easily available information on obesity as a record 
of disease prevalence. QOF data have limitations, and only relate to those people who have 
had a recent measurement and are therefore on each GP practice’s obesity register; it does 
not provide any information on BMI recording in those who are overweight, or on obese 
patients who are not on the practice’s obesity register. What they show is simply the 
number of obese people whose BMI is being measured and monitored in primary care each 
year.  
 
The best estimate of the overall prevalence of obesity comes from survey evidence. The 
Health Survey for England report(28) cited an overall prevalence rate for obesity of 25% in 
England. Similar evidence in Wales gives an obesity prevalence of 24% (29) and 28% in 
Scotland(30). 
 
Taken together these two groups of figures suggest that somewhere around a third of those 
who are obese have had measurement and recording of their BMI in primary care in the last 
12 months and two thirds have not. In the UK the average person consults his or her GP 6 
times a year(31) and there is some evidence to suggest that those who are obese see their 
GPs at a higher rate than average(32). 
 
More work is clearly needed to explore the drivers and barriers to measuring and managing 
obesity in primary care, and the effectiveness of interventions provided. 
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Metric 2: Percentage of adult patients in primary care who have had a measure of alcohol 
consumption or risk in the preceding year. 
 
The full range of practice-based data on alcohol use and morbidity recording in 
consultations is not easily available as is the case for obesity, though GPs regularly use 
standardised and coded tools to record alcohol use and related morbidities.  
 
As considered elsewhere in this report, hazardous and harmful alcohol use is prevalent in 
the UK population. Survey statistics for Scotland demonstrate that nearly 1 in 4 men (23%) 
and around 1 in 6 (17%) women drink at harmful or hazardous levels (33). In England 18 per 
cent of men and 13 per cent of women drink at an increased risk of harm and 5 per cent of 
men and 3 per cent of women drink at higher risk levels(33). Figures for Wales(10) and 
Northern Ireland(1) are broadly comparable.  
 
Alcohol use is related to many areas of social, physical and mental health problems, 
triggering high rates of consultation in primary care. Based on a survey conducted by the 
BMA, the Institute for Alcohol Studies estimates that in Scotland around 6% of GP 
consultations are related to ill health contributed to by alcohol use(34). An indirect estimate 
of the number of GP consultations contributed to by alcohol use within Leeds produced a 
figure of 10% of all consultations(35). Given average consultation rates of 5 per year per 
person, this totals up to 30 million appointments each year across the UK. 
  
However, a consultation for an alcohol-related condition does not mean that alcohol use 
was discussed. In their study in 1998, Kaner et al found that GPs did not routinely enquire 
about alcohol use in their patients and only 1 in 5 GPs felt effective in helping a patient to 
reduce drinking levels(36). Rapley et al’s later survey found GPs were in fact routinely 
enquiring about alcohol use, but lack of time and the need to manage competing multiple 
problems within a single consultation were the main inhibitors to managing a greater 
number of risky drinkers(37). 
 
Data on direct engagement with alcohol issues in a GP consultation can only be sourced 
indirectly. Until 2015 the Practice Team Information (PTI) system collected consultation data 
from general medical practices in Scotland. The most recent PTI figures on GP consultations 
give an estimate of 94,630 alcohol morbidity-coded primary care consultations by 48,420 
patients in 2012/13, and for the purposes of this metric a coded consultation is taken as a 
proxy measure of a primarily alcohol-related consultation(38). Given that Scotland has a 
population of something over 4million adults and a harmful and hazardous alcohol use 
prevalence of around 20% of these it can be estimated that there are 800 000 harmful and 
hazardous drinkers in Scotland. Given that just less than 50 000 patients had a primarily 
alcohol-related consultation in one year, this represents just 5% of the harmful and 
14 
 
hazardous drinking population of Scotland. Other evidence points to higher rates of 
engagement with alcohol consumption by GPs, and in a GP ‘exit poll’ of English patients in 
2004 Aalto found that 11% of those visiting their GP had been questioned by their GP about 
their alcohol use, even if briefly(39). Further indirect evidence comes from a review of 
primary health care records for patients who died from alcohol-related conditions in 
Glasgow in 2003. Twenty one percent had no record at any time of having been advised to 
abstain from alcohol; 23% had received a brief intervention; and 58% had been referred to a 
specialist alcohol service, though 1/3 of these never attended(40).  
 
However, local initiatives have demonstrated that it is possible to achieve significantly 
better performance in primary care in this metric area (box 2).  
 
Panel 3:         The Bolton CCG Implementation example (see Table 1 for data) 
 
National and local reports surrounding alcohol behaviours, suggest that Bolton is, along with 
several other parts of the North West, well above the national average for the prevalence of 
problem drinking. Alcohol harm is amongst the top 5 causes of the life expectancy gap for 
both males and females in the town(41). In order to better understand the drinking habits 
and patterns of use/misuse amongst Bolton’s adult population, a local project was 
developed.  
 
The initiative, which has been running now for 5 years, offers an AUDIT C test every 2 years, 
to all patients aged 16 years and over. Since this time, the Primary Care Development and 
Health Improvement Team, led by Dr Stephen Liversedge, has been working closely with 
GPs and all their staff to increase patient awareness of the dangers posed to good health 
and wellbeing from alcohol misuse. A pathway for Primary Care has also been developed. 
 
The latest data show that since April 2014 129,867 patients have been supported to 
undertake an AUDIT C in Primary Care in Bolton. This accounts for 53.7% of the eligible 
population. Even though all 50 practices in Bolton participate enthusiastically in the 
initiative, some perform better than others. Table 1 demonstrates local data analysis. 
Practices are clustered according to deprivation, age and ethnicity as follows: 
  
Red                  (IMD score 50.75 – 41.23)          High deprivation, high BME, young 
Orange            (IMD score 51.88 – 38.15)          High to mid deprivation, BME/mixed ethnicity,  
                                                                                                                                        young/normal 
Yellow             (IMD score 40.40 – 26.84)          Mid deprivation, mixed ethnicity, normal 
Green              (IMD score 44.95 – 34.71)          Mid deprivation, white, normal 
Blue                 (IMD score 32.77 – 23.37)          Mid to low deprivation, white, normal/old 
Indigo              (IMD score 21.18 – 9.76)            Low deprivation, white, normal/old 
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The variability of AUDIT C data that can be seen in table 1 demonstrates that practices with 
higher levels of deprivation within their population cohort can achieve high activity when 
appropriate support and modest incentives are in place. 
  
As well as meeting the original aim of raising awareness of the dangers of alcohol misuse at 
a population level, this local project carries many other benefits: 
  
• Provides patient education about the benefits of low risk consumption and 
information about the risks of excessive drinking 
• Presents opportunities for patients who are AUDIT C positive (score ≥ 5) to have a 
comprehensive Health Trainer intervention at the surgery to modify unhealthy 
alcohol behaviours 
• Patients who are high risk or dependent drinkers are signposted directly to local 
alcohol services  
• Provides practices with an understanding of an individual’s  alcohol behaviours 
which might assist with future healthcare 
• Alerts clinicians to the need to advise individual patients whose alcohol consumption 
might adversely affect their medications 
• Produces data which can inform commissioning for alcohol services  
• Supplies information to inform future projects 
 
How was this project funded and incentivised? 
 
The initial scheme offered Practices £2.00 per AUDIT C completed. This was funded from 
Public Health, included a training day for all clinical staff and focussed on activity. The 
current scheme now sits within the Bolton Quality Contract, which commissions for 
outcomes across 20 standards and 40 Key Performance Indicators. All 50 Bolton Practices 
are signed up and alcohol screening is one of the KPIs. The local target for 2016-17 is to have 
145,000 current AUDIT Cs completed (60% of the eligible population). Investment has been 
£68k over 2 years, which currently equates to £0.53p per AUDIT C completed. 
Peer pressure amongst practices, arising from freely available local publication of the data 
for all 50 Bolton practices, has helped to drive engagement, as has the investment in 
availability of in-house Health Trainers to modify unhealthy alcohol behaviours. 
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Table 1 NHS Bolton CCG - Audit C June 16 
 Practice 
16+ List 
Size 
Audit C 
Nos. 
Audit 
C - % 
of 
Target 
16+ 
PEER 
AVG 
Audit C 
- % of 
Target 
16+ 
 1 1,523  1,180  77.5% 
72.5% 
 2 2,297  2,071  90.2% 
 3 2,274  2,144  94.3% 
 4 1,021  891  87.3% 
 5 2,965  2,403  81.0% 
 6 2,626  1,340  51.0% 
 7 4,557  2,487  54.6% 
 8 3,545  3,043  85.8% 
64.5% 
 9 3,056  1,374  45.0% 
 10 2,717  1,631  60.0% 
 11 3,228  1,115  34.5% 
 12 3,161  1,733  54.8% 
 13 1,487  1,109  74.6% 
 14 1,610  1,272  79.0% 
 15 1,984  1,623  81.8% 
 16 1,634  1,082  66.2% 
 17 3,236  2,048  63.3% 
 18 6,009  4,393  73.1% 
 19 6,476  4,171  64.4% 
55.0% 
 20 1,710  766  44.8% 
 21 2,752  1,469  53.4% 
 22 2,374  1,196  50.4% 
 23 3,152  2,025  64.2% 
 24 3,941  2,106  53.4% 
 25 9,378  5,229  55.8% 
 26 4,089  1,659  40.6% 
 27 10,750  6,251  58.1% 
56.9% 
 28 5,440  2,591  47.6% 
 29 5,176  1,718  33.2% 
 30 4,043  2,352  58.2% 
 31 2,647  1,474  55.7% 
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 32 5,050  3,805  75.3% 
 33 8,325  5,510  66.2% 
 34 5,090  2,760  54.2% 
 35 4,905  2,465  50.3% 
42.0% 
 36 4,024  2,412  59.9% 
 37 3,281  2,203  67.1% 
 38 10,558  3,764  35.7% 
 39 4,877  2,255  46.2% 
 40 2,479  1,242  50.1% 
 41 6,149  2,402  39.1% 
 42 10,971  3,114  28.4% 
 43 8,424  4,826  57.3% 
49.2% 
 44 6,254  3,555  56.8% 
 45 12,201  4,861  39.8% 
 46 6,212  3,834  61.7% 
 47 16,653  7,676  46.1% 
 48 8,075  3,004  37.2% 
 49 2,311  1,131  48.9% 
 50 4,953  3,102  62.6% 
      
  241,650  129,867  53.7%   
      
      
      
 
 
 
Metric 3: Percentage of adult injecting drug users who have had recent HCV testing  
 
Chronic hepatitis C (HCV) infection is thought to affect 214 000 people in the UK, 
representing 0.3% of the UK population, and 90% of these infections have been acquired 
through injecting drug use. An estimated half of those with chronic hepatitis C infection are 
undiagnosed(42).  
 
A high proportion of current psychoactive drug users attend services for treatment and data 
on testing are routinely submitted to local commissioners by all drug services and collated 
by public health bodies in a number of reports. Further information is available via the 
Unlinked Anonymous Monitoring (UAM) survey of people who inject drugs in contact with 
drug services. 
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Drug misuse treatment is characterised by multiple treatment episodes and drug service 
patients have a comprehensive assessment at the start of each treatment episode which 
routinely covers HCV risk. In the UK in 2013/14 87% of patients had been offered a hepatitis 
C test at the beginning of their most recent treatment episode, and of those more than 2/3 
(67%) accepted the offer(42). Around half of those who inject psychoactive drugs are 
typically found to be hepatitis C antibody positive(8).  
 
In England and Wales, among those who inject only performance and image enhancing 
drugs, 3.6% have antibodies to hepatitis C. Only 32% report ever having been tested for 
hepatitis C.  In Scotland, among those who had only injected image and performance drugs 
during the last six months, 5.1% had antibodies to hepatitis C in 2013-14 and just under a 
third (29%) reported ever being tested for hepatitis C. This had increased from 18% in 2010 
(42). As this group does not use traditional drug services opportunities for HCV testing 
outside drug treatment facilities are needed. 
 
Testing also takes place in general practice, and testing rates have increased year-on-year 
between 2010 and 2014, rising  by 5% between 2013 and 2014 representing 60 000 tests 
across 23 sentinel laboratories each year(42). This suggests that awareness of hepatitis C 
infection in the primary care setting is increasing, and this is particularly important for those 
who have acquired hepatitis C infection from historical injecting drug use and who may not 
have attended drug treatment services for many years, and for those who have acquired the 
infection via an alternative route such as historical blood product transfusion, tattooing or 
body piercing. It has been estimated that around 50% of those with chronic hepatitis C 
infection are not in contact with drug treatment services, and accessing more 
comprehensive data on testing in primary care will be of increasing importance. 
 
Testing for HCV infection in primary care provision in the prison setting is particularly 
important as the prison population represents a particularly high-risk group; however data 
from several different sources suggest significant and continuing under-testing of this 
population group(8). There has been a rise in hepatitis C tests performed from 5.3% of new 
admissions to prison in 2010/11 to 8.6% in 2013/14 suggesting recent increasing awareness 
within the prison estate about the need for HCV testing. 
 
Metric 4: Percentage of adult injecting drug users who have had HBV immunisation 
 
Hepatitis B virus is transmitted by parenteral exposure to infected blood or body fluids, and 
transmission in the UK is predominantly through sexual contact; as a result of blood-to-
blood contact (e.g. sharing of needles and other equipment by injecting drug users or 
‘needlestick’ injuries), and through perinatal transmission from mother to child. Data on 
hepatitis B immunisation in sexual health clinics and primary care practices are not 
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available, and the following metrics are focused on those who are at risk through injecting 
drug use and who are in contact with drug services. The data are taken from collated 
information provided routinely by drug services and from the Unlinked Anonymous 
Monitoring survey  
 
In England, Wales and Northern Ireland, reported uptake of the hepatitis B vaccine for those 
who inject psychoactive drugs (i.e. receiving at least one dose of vaccine) increased from 
around half in 2004 to almost three-quarters in 2014. However, the level of uptake did 
decline from 76% in 2011 to 72% in 2014. Among injecting drug users surveyed in 2014 that 
had never been infected with hepatitis B and who had taken-up vaccination, 61% had 
received three or more doses of the vaccine and had completed the course of 
immunisation. Of those that had not taken-up vaccination 55% (219/396) were currently 
receiving a prescribed substitute drug as part of drug service provision. The non-immunised 
group did utilise other health services where vaccination could have been offered; 62% 
(247/397) had seen a general practitioner; 26% (103/397) had attended an emergency 
department; 14% (56/397) had used a walk-in/minor injury clinic; and 7.8% (31/397) had 
attended a genitourinary medicine clinic(42). These contacts represent lost opportunities for 
vaccination as part of primary prevention. Among people injecting image and performance 
enhancing drugs in England and Wales only 40% reported uptake of the vaccine against 
hepatitis B(42). 
 
Metric 5: Draft and adopt a suite of Read Codes to cover liver disease risk factors, 
diagnoses and interventions to facilitate excellence of clinical care and practice audit and 
performance monitoring 
 
Review by the commission team has identified an opportunity to develop a comprehensive 
set of Read codes relevant to both prevention and management of liver disease and 
associated risk factors.  This project will be taken forwards by the Commission team over 
the next year. 
 
Metric 6:  To ensure that all children born at term in the UK with conjugated jaundice are 
referred to a National Paediatric Liver Unit before they are 8 weeks old 
 
Currently all children with significant neonatal liver disease are referred to one of the three 
national liver units. National data is collected on the age of Kasai Portoenterostomy for 
Biliary atresia and the outcome.  Between January 2009 and December 2013, 230 children 
were diagnosed with biliary atresia in England and Wales;   75 (i.e. 32.6%)   were older than 
the recommended age for operation (>56 days old) at time of Kasai Portoenterostomy or 
laparotomy, 7/75 had a primary transplant (1). Further education and awareness of the 
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importance of early diagnosis of neonatal liver disease will be addressed through initiatives 
from PHE and the Children’s Liver Disease Foundation (CLDF).  
 
 
Recommendation 2:   Establishment of acute liver services in district general 
hospitals linked with 30 regional specialist centres for more complex 
investigations and treatment, and increased provision of medical and nursing 
training in Hepatology  
 
       Panel 4:     Metrics for Recommendation 2 
1. Number of DGHs with liver units (>2 consultant hepatologists) 
2. Number of regional specialist units 
3. Number of consultant hepatologists in post 
4. Number of DGHs with 24hour emergency endoscopy cover 
5. Number of DGHs enrolled into QuEST programme 
6. Number of DGHs with multidisciplinary alcohol care teams 
 
 
In presenting the metrics for this recommendation, Dr Mark Hudson and Dr Jess Dyson have 
obtained up to date figures on hospital staffing levels and facilities for liver disease in the UK 
through a new and complete survey of hospital trusts. Of the 207 hospitals approached, 
100% provided information. Overall, a total of 221 whole time equivalent (WTE) consultant 
hepatologists and 305.7 gastroenterologists with an interest in hepatology were identified. 
The data for the devolved countries is provided in Table 2 and expressed as WTE per 105 
population. The provision of liver services as defined by WTE staffing levels in the UK is 
summarised in Figure 2. Outside of transplant centres, only 21 (10%) of centres have ≥3 
hepatologists, meeting the criteria for “large” units coming within the category of specialist 
regional centres. Only 16 of the remaining hospitals in the UK would meet the criteria for an 
adequately staffed acute service (2 hepatologists and 2 or more gastroenterologists with an 
interest in hepatology). 
 
Considering England alone, a total of 193.8 WTE consultant hepatologists were identified as 
compared to 122 in 2010(43); a 59% increase. However, 54.7 (28%) of these were in the 6 
English transplant centres and 69.6 (36%) were in the 18 “large” units within the category of 
specialist regional centres. Of the remaining 135 hospitals, only 16 (12%) meet the criteria 
for an adequately staffed DGH acute service (2 hepatologists and at least 2 
gastroenterologists with an interest in hepatology). Table 2.  
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Table 2: Summary for UK and devolved nations of hepatologists per 10
5
 population, 
hepatology provision in terms of staffing levels, Level 2 services, endoscopy and TIPSS service 
and enrolment in LIVER QuEST 
 Consultant 
Hepatologists 
(WTE) 
Number of 
Acute DGH (>2 
WTE 
hepatologists & 
>2 
gastroenterolog
ists with 
interest in 
hepatology) 
Number of 
Regional 
Specialist Liver 
Units 
(services) 
LEVEL 2 
Number  of 
Regional 
Specialist Liver 
Units 
 (>3 WTE 
hepatologists) 
“LARGE” 
Units 
(excluding large 
centres) with 
24 hour OOH 
and n(%) able 
to manage 
varices 
TIPSS 
Provision 
UK 221 
 
0.34 per 
100,000 
population 
(64.9 million) 
16 23 (excluding 7 
transplant 
centres) 
21 (excluding 7 
transplant 
centres) 
143/183 (78%) 
[120/143 (84%)] 
44/207 
(21%) 
England 
 
193.8 
 
0.35 per 
100,000 
population 
(54.7 million) 
16 
 
18 
(excluding 
6 transplant 
centres) 
18 
(excluding 
6 transplant 
centres) 
117/135 (87%) 
[104/117 (89%)] 
34 / 159 
(21%) 
Scotland 20.6 
 
0.39 per 
100,000 
population (5.3 
million) 
0 3 
(excluding 1 
transplant 
centre) 
2 
(excluding 1 
transplant 
centre) 
13/22 (59%) 
[8/13 (62%)] 
8/22 
(36%) 
 
Wales 2.6 
 
0.08 per 
100,000 
population 
(3.1 million) 
0 1 0 5/16 (31%) 
[5/5 (100%)] 
1/16 
(6%) 
Northern 
Ireland 
4 
 
0.22 per 
100,000 
population (1.8 
million) 
0 1 1 8/10 (80%) 
[3/8 (38%)] 
1/10 
(10%) 
 
 
As well as stratifying centres in terms of the numbers of WTE consultant hepatologists, the 
survey also looked at the services provided. A Level 2 specialist centre is defined as one that 
provides out of hours (OOH) endoscopy including the management of varices; transjugular 
intrahepatic porto-systemic shunts (TIPSS); an HCC/HPB multi-disciplinary team meeting; 
medical loco-regional treatment for HCC; antiviral treatment for hepatitis C (in England as 
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part of an HCV ODN); liver histopathology; dedicated liver clinics, and a specialist nurse 
team. 
 
Using this definition, only 18 centres in England and 3 in Scotland (outside of the liver 
transplant centres), 1 in Wales and 1 in Northern Ireland meet the Level 2 criteria for a 
specialist liver unit. It is also noteworthy that 5 of the 21 “large” centres (who have ≥3 
hepatologists) in the UK do not meet these criteria although 7 of the 179 centres that have 
<3 WTE hepatologists can provide these services. Mapping of the district general hospitals 
(DGHs) and regional specialist centres against liver disease hospital admissions and standard 
mortality rates for liver disease in England are shown in Figures 1 and 2. The maps suggest 
that there is now reasonable availability of specialist liver services in the majority of regions 
in England. This is particularly so if the hepatitis C operational delivery networks (ODNs) are 
included. However, there remain many DGHs that have inadequate hepatology support. In 
England, 55% (88) of all hospitals do not have a specialist hepatologist and 47 (30%) 
hospitals do not have a dedicated liver clinic (excluding viral hepatitis). 
 
 
 
Figure 4: Provision of liver services as defined by WTE staffing levels in the UK (large centre = 
≥3 WTE hepatologists, DGH = 2 hepatologists and ≥2 gastroenterologists with an interest in 
hepatology, none = no WTE hepatologists or gastroenterologists with an interest in 
hepatology, in between = anything between DGH criteria and none)  
 
The NCEPOD(43, 44) report in July 2015 highlighted major deficiencies in the care received 
by patients suffering severe gastrointestinal haemorrhage as a consequence of cirrhosis and 
variceal bleeding. The mortality rate was high at 32% with 37% not receiving prophylactic 
antibiotics despite recommendations in all guidelines and strong evidence that this reduces 
mortality(45, 46). Despite the failure to control bleeding in almost a third of patients, only 
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13 hospitals were reported to have a 24/7 TIPSS service. The findings in the liver survey with 
respect to OOH provision for endoscopy are summarised in Table 2. The data for England 
excludes the transplant and large units. The provision of out of hours (OOH) endoscopy 
services varied widely between the devolved nations. In England, 117 (87%) of hospitals 
provide emergency 24 hour endoscopy cover although only 104 of these can manage 
varices. In Scotland, Wales and Northern Ireland, 59% (62%), 31% (100%) and 80% (38%) of 
centres provide 24 hour endoscopy cover, respectively (with the figures in brackets 
representing the proportion of endoscopists who are able to manage varices). Of the 34 
centres in England recording a TIPSS service, 14 perform <10 procedures per year, and in 
Scotland, 3 of the 8 centres providing TIPSS performed <5 in the past year (Table 2) which 
must raise concerns as to the safety and sustainability of such services. In Wales and 
Northern Ireland, there are single centres for the whole country making access for 
emergency procedures difficult. 
 
The survey also collated information regarding numbers of liver nurse specialists and viral 
hepatitis nurse specialists. These are presented in Table 3, which again highlights the wide 
variation between the devolved nations per 105 of the population. 
 
Table 3: Summary for UK and individual home nations of specialist nurse provision, alcohol 
liaison services and liver fellows 
 Liver Nurse Specialists Viral Hepatitis Nurse 
Specialists 
Alcohol liaison service 
UK 163.5 
0.25 per 100,000 
population 
(64.9 million) 
223.5 
0.34 per 100,000 
population 
171/207 (83%) 
England 134 
0.24 per 100,000 
(54.7 million) 
175 
0.32 per 100,000 
133/159 (84%) 
Scotland 18 
0.34 per 100,000 
(5.3 million) 
31 
0.58 per 100,000 
18/22 (82%) 
Wales 9.5 15.5 12/16 (75%) 
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0.31 per 100,000 
(3.1 million) 
0.5 per 100,000 
Northern 
Ireland 
2 
0.11 per 100,00 (1.8 
million) 
2 
0.11 per 100,000 
8/10 (80%) 
 
 
Number of DGHs with multidisciplinary Alcohol Care Teams 
 
The proportion of hospitals providing some level of alcohol liaison service is similar across 
each of the nations in the UK. However, the number of hospitals with formal, 
multidisciplinary alcohol care teams (ACTs) is uncertain. The evidence base for the role of 
ACTs, together with the 6 key elements of a model team, are well described(47). The 
establishment of a consultant-led, multidisciplinary ACT and a 7-day alcohol specialist nurse 
(ASN) service were also 2 of the principal recommendations of the National Confidential 
Enquiry into Patient Outcome and Death (NCEPOD) report (48) which highlighted the delays 
in referral of patients for specialist care and missed opportunities for brief interventions 
during previous admissions. The present survey shows that the number with formal 
multidisciplinary Alcohol Care Teams was uncertain although some level of alcohol team 
was present in the majority of hospitals in England and the devolved nations. In a small, 
local, London-based survey in 2009, only 10% of hospitals surveyed had a multidisciplinary 
alcohol care team consultant lead and 42% had an alcohol specialist nurse service(49).  
 
In 2014, Public Health England (PHE) published data on hospital alcohol care teams and 
alcohol specialist nurses(50). Encouragingly, in a 2015/16 follow-up survey, at least 76 out of 
a total of 116 hospitals surveyed (66%) had a consultant lead. Around 45% were 
gastroenterology/hepatology led, 18% by psychiatry and 11% by emergency medicine. 
Almost a quarter of services were clinically led by nurses. However, only 68% of hospital 
that responded to PHE’s 2015 survey have teams staffed adequately to provide seven day 
cover and deliver the potential impact demonstrated by Royal Bolton or Salford(47). 
 
PHE analysis of secondary care alcohol specialist services has identified that, regardless of 
geographical location or size of hospital, the most impactful alcohol care teams and those 
providing a seven day service, led by a senior clinician with dedicated time for the team and 
evidence-based interventions. Alcohol care teams facilitate identification of alcohol 
misusers in hospitals and deliver appropriate packages of care provided by multidisciplinary 
teams. This requires dedicated sessional input from senior clinicians and at least three other 
clinical staff in order to facilitate seven day working throughout the year. 
25 
 
 
Care bundles and Liver QuEST accreditation 
 
Some progress has been made during this year with development of the “Cirrhosis Care 
Bundle” to standardise early treatment (within 24 hours of admission to hospital) for 
patients with decompensated cirrhosis. Results of implementation of the “bundle”, which 
has been piloted in the Newcastle upon Tyne NHS Hospitals Foundation Trust as a successful 
CQUIN target, show that patients with a completed care bundle are more likely to have 
appropriate management. A comparison of pre- and post-bundle audit data from three 
English hospitals showed that patients with a completed care bundle are significantly more 
likely to undergo a diagnostic ascitic tap to exclude spontaneous bacterial peritonitis 
(p=0.020), have an accurate alcohol history documented (p<0.0001) and be given 
prophylactic antibiotics following variceal haemorrhage (p=0.0096)(51). 
Some progress has also been made in implementation of the Liver Quest project for 
accreditation of hospital services. Liver QuEST(52) is an evolving quality assurance 
framework that aims to improve the care of patients with liver disease across England. The 
project is sponsored by the Royal College of Physicians and has the backing of the patient 
groups, the British Society of Gastroenterology, The British Association for the Study of the 
Liver and the Lancet Commission. This process has been piloted in 6 units across England 
and the learning from these visits was recently reviewed. Early themes arising from the 
process include an underutilisation of information technology and a failure in demonstrating 
performance against simple key performance indicators in emergency care (such as 
antibiotic prescription in variceal bleeding). To date 24 hospitals have engaged with Liver 
QuEST including 8 DGHs. Currently it is in the process of utilising the operational delivery 
networks associated with Hepatitis C. It is also working with NHS Wales to involve their liver 
services within the scheme with a plan to encompass the other devolved nations over the 
coming year. 
 
Recommendation 3: A national review of liver transplantation to ensure 
better access for patients and to increase capacity 
Panel 5:   Metrics for Recommendation 3   
3.1    Number of patients treated 
3.2    Transplant activity normalised to waiting list 
3.3    Waiting time to transplant normalised by blood group 
3.4    Primary offer acceptance rate of used whole organs 
3.5    Utilisation of marginal donors 
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The rate of liver transplant activity is the primary metric of performance and the number of 
transplants performed in 2015-6 was 917 and in line with activity over the last three years. 
There was a modest 4% decrease in the number of patients on the waiting list on the 31st 
March 2016.  There transplant rates fall short of the targets set by the NHS Blood and 
Transplant T2020 strategic review. 
The Lancet Commission continues to hold the view that liver transplant services should be 
subjected to a fundamental review but there is no evidence to date that this will be 
forthcoming. However, the first formal peer review process of individual programmes is 
scheduled for late 2016. An extensive range of quantitative measures will be evaluated that 
measure performance against agreed national service specifications as well as outcomes. 
There may also be an opportunity during this review to scope capacity for expansion if the 
hoped for increase in donor organs materialises.    
Equity of access to liver transplant services and the rate of organ utilisation across all the 
programmes are cardinal metrics of performance. The most recent report on liver 
transplantation published by NHS Blood and Transplant confirms the continuing crude 
differences by geographical region and access to liver transplantation. The highest 
transplant rates per million population were in Scotland (19.1) and Northern Ireland (17.9) 
and the lowest in the South of England (9.3). The remaining Strategic Health Authority areas 
had rates in the 13.0-14.4 range. 
Waiting times and the risk of death on the waiting list are also dimensions of equity of 
access and historically there have been significant differences between centres with respect 
to these parameters. The metrics designed to monitor this aspect are transplant activity 
rates normalised to the size of the waiting list and the waiting times to transplantation for 
each of the blood groups. However, significant progress has been made to preferentially 
direct organs to the patients most likely to benefit from the transplant and a new national 
offering sequence is scheduled to operate from summer 2017. The initial offer will no longer 
be directed to centres but to the highest ranked patient in the country. The principle of 
directing the organs to those most likely to benefit will be balanced with the objective of 
maximising utilisation of donated organs. The new system should improve equity of access 
and is expected to reduce mortality on the waiting list by 50%.  Another dimension of equity 
of access is the demonstration of consistency in the co-morbidity profiles considered 
acceptable in patients being listed for liver transplantation. 
The percentage of livers retrieved but not transplanted has increased from 8.2% to 16.6% 
over the past decade, with a 4% point increase in the last two years. While the cause of this 
trend is likely to be multifactorial, the possibility that it includes an element of impaired 
ability to cope within the service needs to be given due consideration. However, organ 
utilisation should be consistent across the service and 2 metrics to track this have been 
designed: 
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-  the acceptance rate on first offer of a whole organ, 
-  the utilisation of organs falling within an agreed definition of marginal organs. 
At present, there is considerable variance in practice between centres with declines rates 
being higher in those with shorter waiting lists. The extent to which these differences are 
logistical or cultural needs to be clarified.  
 
Recommendation 4: Specialist paediatric services & continuity of care in 
transition arrangements for children with liver disease reaching adult life 
 
 
Panel 6:  Metrics for Recommendation 4  
4.1 Reduction in out-patient DNA rates in patients transitioned to adult 
services in the 3 main liver centres to less than 15%. 
4.2 Reduction in graft loss and/or death in 16-24 year olds post transition  
4.3 Educate adult physicians in paediatric liver disease/transition by 
supplementing adult curriculum 
 
 
Between 2008 and 2015, 667 young people transitioned into adult services at Birmingham 
Children’s Hospital (BCH) and Kings College Hospital (KCH), of whom 17 died (2.5%) (Table).  
Historic data from all three national centres (BCH, KCH and Leeds) demonstrated that 
approximately 22% did not attend outpatient clinics in adult services despite a specialist 
transition service(53, 54), demonstrating the need for more focussed management and 
support.  
 
The 3 national paediatric liver centres are now using a validated self-management tool to 
empower young people to manage their condition and identify specific areas where more 
multidisciplinary support is required to facilitate the transition process. 
 
Recognition that additional education and training for adult hepatologists on childhood liver 
disease is needed has led to the development of a draft curriculum which has been 
submitted to the relevant specialist committees to be included for ‘core’ training for 
Gastroenterology and Hepatology trainees. 
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Table 4: Outcome for Young People attending two national Paediatric Liver Units# in England 
post Transition to Adult services 
 
 
2008 – 2013  
Transferred to Adult services  667 
Deaths post Transition 
 
10 
     Post-Transplant 
 
8 
     Liver Disease 
 
2 
Total 1.5% 
 
 
# Birmingham Children’s Hospital (BCH), Kings College Hospital (KCH) 
 
 
 
 
Recommendation 5: Measures to reduce overall alcohol consumption in the 
country  
 
Panel 7:    Metrics for Recommendation 5 
5.1: Policy metrics 
5.2: Overall alcohol consumption in country  
5.3: Number of admissions from alcoholic liver disease  
5.4: Number of deaths directly due to alcohol consumption  
5.5: In hospital ALD mortality  
5.6: Hospital and Community Alcohol Services 
5.7: Survivals for liver admissions  
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Metric 5.1:  Policy metrics 
Table: 5    Policy Metrics 
 England Wales Scotland N Ireland 
MUP Opposed to 
MUP  
Legislation in 
progress 
MUP bill 
passed, legal 
verdict awaited 
Legislation in 
progress 
Taxation Not devolved, Tax cuts to drinks industry worth £3.55 billion according 
to 5 year Treasury projections since 2013  
 
The UK government theoretically remains committed to the Alcohol Strategy published in 
March 2012 in which David Cameron stated: “When beer is cheaper than water, it’s just too 
easy for people to get drunk on cheap alcohol at home before they even set foot in the pub. 
So we are going to introduce a new minimum unit price (MUP). For the first time it will be 
illegal for shops to sell alcohol for less than this set price per unit. We are consulting on the 
actual price, but if it is 40p that could mean 50,000 fewer crimes each year and 900 fewer 
alcohol-related deaths a year by the end of the decade.” Mr Cameron went on to say: “Of 
course, I know the proposals in this strategy won’t be universally popular. But the 
responsibility of being in government isn’t always about doing the popular thing. It's about 
doing the right thing.” However, MUP was postponed indefinitely following lobbying from 
the drinks industry (55, 56) and the Government has made no moves to bring forward any 
effective measures since, including protection of children from alcohol marketing. 
 
There have been two subsequent developments, Public Health England (PHE) were 
commissioned by the UK and devolved governments to produce two reports one of UK 
alcohol policy and a further report of alcohol related harm to third parties, i.e. people 
harmed as a result of drinking by other people. PHE have formally reviewed the evidence for 
alcohol policy, and are due to publish this report in autumn 2016. 
 
The UK Chief Medical Officers published reviewed drinking guidelines in January 2016, 
stating that any amount of alcohol intake can increase the risk of developing a range of 
illness including cancer, recommending a weekly intake of no more than 14 units with 
several drink free days each week(57). The report did not address higher risk and harmful 
drinking, but did conclude that since the previous guideline in 1995(58) new evidence has 
outlined that the risk of cancer starts from zero alcohol, intake and rises in a linear fashion. 
The report also addresses the putative health benefits of alcohol, concluding that this 
evidence was considered less strong than previously, and that a reduced risk in the UK is 
significant only for women aged 55 or older. The 14 unit guideline on regular drinking would 
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be consistent with a little under a 1% lifetime risk of death from alcohol for people who 
follow this consistently(57). 
     
Metric 5.2: Alcohol consumption 
 
Sources of data for alcohol consumption include HMRC receipts and population surveys, 
with surveys recording 55-60% of the consumption recorded by HMRC. Overall HMRC 
receipts increased until 2008, when a 2% above inflation duty escalator was introduced at 
the same time as the economic downturn, and are now increasing once more (Figure 1).  
 
 
Figure 5:  Data from HMRC clearance show gradually increasing consumption of alcohol in 
the UK until 2008 when the 2% above inflation duty escalator was introduced, since when 
consumption transiently decreased, but is now rising strongly once more. There has also 
been marked shift towards the consumption of stronger alcohol, with a decrease in 
consumption of beer, and increased consumption of wine, spirits and cider(59)  
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The UK Opinions and Lifestyle Survey (OPN) found that 58% of the UK population had drunk 
in the previous week, with around 18% of the highest earners drinking on 5 or more days, 
compared with 8% of lowest earners. Wales (13%) had the highest proportion of people 
drinking more than 14 units / week, compared with Scotland (12%) and England (8%).  
 
Analysing HSE data from 2014 for the total amount of alcohol consumed by drinkers 
categorised by level of weekly consumption (Table 1) reveals that 24% of alcohol was 
consumed by low risk drinkers, 76% was consumed by higher risk drinkers, of which 52% 
was consumed by people drinking more than twice the recommended guideline(60). 
Comparing the distribution with HSE data from 1991-2, the proportion of alcohol consumed 
by extreme drinkers drinking more than 75 units /week has increased from 13% to 17%.  
 
 
cohort
1991-2 2014
Combined weekly units Combined weekly units
Count Column N % Sum Count Column N % Sum
Weekly alcohol rating zero
>0-14
15-28
29-75
>=75
678 9.6% 0 0.0% 1434 18.6% 0 0.0%
4686 66.4% 19040 25.2% 4633 60.0% 19176 24.6%
960 13.6% 19363 25.6% 922 11.9% 18841 24.2%
641 9.1% 27463 36.3% 629 8.2% 27051 34.7%
88 1.2% 9751 12.9% 98 1.3% 12830 16.5%
 
Table 6: Analysis of HSE data from 1991-2 and 2014 with total amount of weekly units 
consumed categorised according to weekly alcohol rating.  The proportion of teetotallers 
doubled, extreme drinkers increased slightly from 1.2% to 1.3% whereas the proportion of 
total alcohol consumed by extreme drinkers increased from 13% to 17% (Yates Chi Sq 
p<0.0001).  
 
 
Metric 5.3 and 5.4: Alcohol related hospital episodes and deaths 
Trends in alcohol related hospital episodes for England show a steady increase peaking in 
2012, and relatively stable in the 2 years since. Directly attributable alcohol related deaths 
increased steadily in England and Wales throughout the 1980’s, 1990’s and 2000’s. The 
majority of these deaths were a result of alcohol related liver disease, and there is a self-
evident relationship between alcohol-related deaths and increasing affordability of alcohol 
as alcohol duties were not increased in line with incomes (Figure 3). The patients dying of 
directly alcohol related are extreme drinkers, the average weekly consumption of patients 
with alcohol related cirrhosis is around 150 units, and of patients with alcohol dependency 
even higher at around 180 units, and so on the whole these patients are drinking the 
cheapest alcohol they can find(61, 62). Alcohol related deaths are strongly linked to health 
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inequalities, many of these patients are already spending much of their disposable income 
on alcohol and are sensitive to price changes(63, 64).  
In the budget of 2008 alcohol duty was increased and a 2% above inflation escalator 
introduced, the subsequent decrease in affordability coincided with a change in the trend in 
alcohol related mortality. We have hypothesised that this change was a direct result of 
changes in the price of alcohol combined with the impact of an economic downturn on 
incomes(65) and predicted that alcohol mortality would rise following the repeal of the 2% 
duty escalator in 2013 and the subsequent tax cuts. Alcohol related deaths increased in 
2014 (reported November 2015) and the figures for 2015 will be reported in November 
2016(66, 67).  
 
 
Figure 6: Trends in wholly attributable hospital admission episodes  
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Metric 5.4: Number of deaths directly due to alcohol consumption (ONS) 
Data from Statistics on Alcohol June 2015(68) 
 
Data for Scotland for this metric, compiled from data collected by the Office for National 
Statistics(69),  is presented in graphic form within the Report from Scotland later in this 
document. The graph shows the number of deaths registered each year against the 5-year 
moving average and demonstrates a year on year increase from 1992 peaking in 2002. Since 
that date there has been a series of staggered decreases to the present level (2015) of 
around 1100 deaths per annum. 
 
Metric 5.5: Alcohol related deaths 
In 2015, there were 1,150 alcohol-related deaths, on the basis of the current definition a 
decrease of 2 (0.2 per cent) compared with 2014, and the third lowest annual total since 
1997.  The number of alcohol-related deaths was relatively stable, at roughly 600 per year, 
during the 1980s. It then increased rapidly during the 1990s and early 2000s, to around 
1,500 per year in the mid-2000s. The figure of 1,546 in 2006 was the largest so far recorded: 
since then, the trend has appeared to be generally downward, as the rises in some years 
have been small (compared to the falls in the other years) and could well be due to year-to-
year variability. Deaths in 2015 consisted of 764 male deaths and 386 female deaths, 
continuing a long term pattern(70). 
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There were approximately 16 chronic liver disease deaths per 100,000 population in 
Scotland in 2014, similar to the rate in 2013. In 2014, male mortality rates for CLD were 
twice as high as those reported for women (21 per 100,000 compared to 10 per 100,000 
population). Between 1993 and 2003, there was a sharp increase in CLD mortality rates 
overall and in both men and women: for men, the mortality rate increased from 14 per 
100,000 to 35 per 100,000 population and for women, from 8 per 100,000 to 16 per 100,000 
population. Since 2003 the rates have decreased for both men and women. In 2014, CLD 
mortality rates were highest in people aged 55-64 years (36 per 100,000 population). 
 
Metric 5.6 Hospital and Community Alcohol Services 
 
The most effective and cost effective means to reduce alcohol related deaths and 
admissions is to reduce alcohol consumption in extreme and harmful drinkers by increasing 
the price. We also need to detect and intervene earlier in liver disease. Once patients 
present with liver disease it is tragically too late in most cases, and there is little evidence 
that any of our therapeutic strategies improve survival, but we do know that the main 
determinant of long term survival is whether the patient abstains from drinking(71). As a 
result efforts have been made to integrate alcohol treatment services with liver units in 
acute trusts. Data obtained from Iain Armstrong at Public Health England indicate that of 
192 district general hospitals in England, currently (2015-16 financial year) 10-13 hospitals 
are known to have no service. 116 are known to have an alcohol service in March 2016 a 
further 42 were known to have services in 2014. So the total number of hospitals with 
services is probably between 116 and 158. Since 2014, 6 hospitals are known to have lost 
funding for their alcohol specialist services, while 2 now have services that previously did 
not. Funding is generally a mixed economy from LA public health and CCGs or provider 
trusts, often in 
partnership. In 
December 2015, a 
third of services were 
secure in their funding 
beyond 2018/19, 
nearly half were secure 
until at least 2018/19. 
However, a good deal 
of funding is short 
term and over a third 
were not assured of 
funding beyond the 
next financial year 
(2016/17) and 20 had Figure 8: In-hospital mortality of liver disease for acute                               
trusts in England 
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no funding identified for the coming financial year (2016/17).  
 
There is concern that further local authority cuts will result in a significant loss of alcohol 
services in England. This contrasts with N. Ireland and Wales, where alcohol services are 
attracting significant Health Board investment and are being progressively developed. The 
Wales Liver Plan has made a firm commitment to develop ACTs embedded in secondary 
care with assertive outreach teams, a clinical lead has been appointed in 3 of the 6 health 
boards so far and alcohol specialist nurses have increased from 13 to 17. In N. Ireland 10 
alcohol specialist nurses will increase from 10 in 2013 to 18 in 2016, aiming eventually for 28 
to ensure a 7-day alcohol specialist nurse service. In Scotland the current Alcohol strategy is 
undergoing a refresh and proposals for such teams are being considered. 
 
Metric 5.7: Survival of alcohol related liver disease admissions 
The NCEPOD report of 2013 identified a number of shortcomings in the hospital treatment 
of patients with alcohol related liver disease, and in previous Commission reports we have 
outlined the variation in-hospital mortality rates between trusts, with recommendations for 
more specialist liver units across the UK(48). However there have been steady advances in 
the management of patients with alcohol related liver disease, endoscopic banding of 
varices, Terlipressin treatment of hepatorenal syndrome and intensive care(72-74). As a 
result of these or other factors there have been steady year on year improvements in in-
hospital mortality across acute trusts in the UK (figure 4). 
Baseline data for longer term survival has been calculated using NHS data (2005-2014) 
supplied by liver units in Southampton, Plymouth, Newcastle and Sunderland (Figure 5), 5 
year survivals remain poor varying from around 85% for viral hepatitis, to 65% for alcohol 
related liver disease and 35% for primary liver cancer.  
One year survival metrics will be used to measure improvements in survival against the 
2005-2014 baseline (Figure 6). The very high one year mortality of pateitns with alcohol 
related, cryptogenic liver disease and primary liver cancer reflects the late diagnosis of the 
majority of liver cirrhosis. 
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Figure 9:  Kaplan Meier survival plots (months) from the time of first liver admission pf 
patients from Southampton, Plymouth, Newcastle and Sunderland, admitted between 2005-
2014 
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Data from Scotland relating to Metric 3: 
Number of admissions from alcoholic liver disease 
 
Figure 10: shows the trends in stay rates for four conditions; alcoholic liver disease, alcoholic 
liver failure, Alcoholic acute hepatitis and alcoholic cirrhosis. EASR European age 
standardised rate(69) 
In 2014/15, there were 35,059 alcohol-related general acute hospital stays in Scotland; a 
standardised rate of 672 stays per 100,000 population. This is a continuation of the fall in 
rates seen since 2007/08. However, in 2014/15 rates for stays were still more than four 
times higher than at the beginning of the time trend. The decrease since 2007/08 has been 
predominantly driven by the reduction in more ‘acute’ conditions, such as Harmful Use and 
Toxic Effect, whereas the more ‘chronic’ conditions, such as Alcohol-related Liver Disease 
have increased. The increase in hospital stays seen up to 2007/08 has been driven to a large 
extent by repeat visits rather than new patients being admitted to hospital. In 2014/15, 
alcohol-related stays in general hospitals were nearly 8 times more frequent for individuals 
living in the most deprived areas compared to the least deprived areas. The rate for 
alcoholic liver disease 6,963 stays in 2014-2015 has increased over the last two years and 
showed a much flatter curve in the previous years than for alcohol-related conditions 
overall. The breakdown of alcohol related liver disease shows most of the rise is due to 
cirrhosis and to repeat admissions, with the number of new patients being relatively static. 
Suggesting that we are not reducing the number of patients developing alcohol related 
cirrhosis but they are more likely to survive there first admission.  
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Recommendation 6: Promotion of healthy lifestyles to reduce obesity & the 
burden of NAFLD 
 
 
Panel 8:   Metrics for Recommendation   
 
6.1 Prevalence of child and adult obesity 
6.2 Adoption of Health Select Committee priorities for childhood obesity 
6.3 Prevalence of NAFLD/NASH in secondary care 
6.4 Number and proportion of patients with NAFLD as a diagnosis 
assessed for liver transplantation 
6.5 Number of bariatric surgery operations per 100,000 population 
 
 
Obesity and its effects on health, such as non-alcoholic fatty liver disease, continues to be a 
major burden to the UK which will require concerted efforts by government, healthcare  
professions and the public if it is to be addressed. This section will provide objective 
assessments of the prevalence of obesity in children and adults in the UK as well as data on 
the subsequent downstream consequences of obesity on liver disease. 
 
Metric 6.1: Prevalence of child and adult obesity  
 
Data from Health Survey England (HSE) along with that from equivalent surveys in Wales, 
Scotland and Northern Ireland demonstrate the scale of the problem affecting both adults 
and children (Figure xx). Ongoing monitoring of these data will be an important guide to the 
current burden of obesity as well as providing a critical benchmark to assess the impact of 
strategies to reduce it over the longer-term. 
 
Data on childhood obesity are not available from all of the UK at this stage. Collation of 
these data along with cross-referencing with data from the National Child Measurement 
Programme (NCMP) will be important to build an accurate picture of childhood obesity. 
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Figure 11: Prevalence of adult obesity in the United Kingdom 
 
 
 
 
 
Metric 6.2:    Adoption of Health Select Committee priorities for childhood obesity.  
 
The recent Health Select Committee report(75) identified key overarching objectives to 
protect families from the pressures of unhealthy food marketing by changing the 
obesogenic environment; to enable individual choice by making healthy food choices and 
access to opportunities for physical activity easier; to inform families of the risks associated 
with poor diet and physical inactivity; and to support children and families to lose weight 
and maintain a healthy weight. The government published its childhood obesity plan(76) in 
2016. Table 7 assesses the extent to which the plan meets recommendations from the 
Health Select Committee. Very few of the recommendations are addressed in the Plan, and 
most of those that are, rely on voluntary commitments from industry.  
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Table 7: Measures in the government’s child obesity plan measured against 
recommendations of the Health Select Committee. 
 
Recommendations of Health 
Select Committee 
Government’s Child Obesity Plan Traffic Light 
Assessment 
Strong controls on price 
promotions of unhealthy 
food and drink 
Not included RED 
Tougher controls on 
marketing and advertising of 
unhealthy food and drink 
Not included RED 
A centrally led reformulation 
programme to reduce sugar 
in food and drink 
Launch of a voluntary sugar reduction 
programme with aim of reducing 
overall sugar by at least 20% by 2020, 
including a 5% reduction in year one. 
Not clear what fines/levies will be 
implemented if targets are not 
achieved. 
AMBER 
A sugary drinks tax on full 
sugar soft drinks, in order to 
help change behaviour, with 
all proceeds targeted to help 
those children at greatest 
risk of obesity 
A soft drinks industry levy will be 
introduced in England from 2018, with 
the revenue from it invested in 
programmes to reduce obesity and 
encourage physical activity and 
balanced diets for school age children.  
GREEN 
Labelling of single portions of 
products with added sugar 
to show sugar content in 
teaspoons 
Establish a review of additional 
opportunities to go beyond current 
labelling scheme. Examples given 
include clearer visual labelling, such as 
teaspoons of sugar in packaged food 
and drink.  
AMBER 
Improved education and 
information about diet 
Discussion of use of information 
technology such as the Change4Life 
Sugar Smart app. No further 
investment nor new programme. 
RED 
Universal school food 
standards 
Funding generated from the sugar 
levy will be diverted towards the 
Primary PE and Sport Premium which 
includes school healthy breakfast 
clubs. From September 2017, a 
voluntary health rating scheme for 
primary schools will be taken into 
account during Ofsted inspections. 
The new School Food Standards will 
be updated in the light of refreshed 
government dietary 
recommendations. 
AMBER 
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The majority of schools are subject to 
the School Food Standards. However, 
some academies and free schools are 
not. There will be a campaign by the 
Secretary of State for Education  
encouraging all schools to commit to 
the standards.  
 
Greater powers for local 
authorities to tackle the 
environment leading to 
obesity 
No change in local authority power.  
There will be further encouragement 
for local authorities to adopt the 
Government Buying Standards for 
Food and Catering Services (GBSF) 
standards, particularly in leisure 
centre vending machines. This will be 
accompanied by the full uptake of 
GBSF in central government 
departments  
RED 
Early intervention to offer 
help to families of children 
affected by obesity and 
further research into the 
most effective interventions. 
Re-committing to the Healthy Start 
scheme, which provided an estimated 
£60 million worth of vouchers to 
families on low income across England 
in 2015/16. These can be exchanged 
for fresh or frozen fruit or vegetables 
and milk. No other plans. 
 
RED 
 
 
Metric 6.3: Prevalence of NAFLD/NASH in secondary care 
 
Hospital episodes statistics (HES) data provide information on patients admitted to hospital 
with NAFLD/NASH as a diagnosis. Whilst these data will be influenced by greater coding of 
NAFLD/NASH they do capture the increased morbidity/mortality of patients with 
NAFLD/NASH, providing information on the burden of NAFLD/NASH on hospital bed usage. 
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Figure 12: Finished consultant episodes in UK in which NAFLD was a coded diagnosis 
 
 
 
At present there is significant variation in the identification and referral of patients with 
NAFLD reflecting the lack of clear guidance. A BSG-led group with representation from the 
relevant stakeholders, including patient groups, is reviewing evidence and best-practice on 
the management of abnormal liver function tests and will report in late 2016 with new 
guidance. This should help standardise care, reduce unnecessary referrals and ensure that 
patients needing further investigation are identified at the appropriate stage. 
 
Metric 6.4:  Number and proportion of patients with NAFLD as a diagnosis assessed for 
liver transplantation  
This metric provides information on the impact of obesity on inducing end-stage liver 
disease due to NAFLD, as well as providing a measure of the provision of adequate services 
for such patients with NAFLD/NASH. 
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Figure 11: Number of adult elective NHS patients waiting for a transplant at the January 
snapshot of the liver transplant list in the UK 
 
 
 
 
 
 
 
 
Figure 13: Patients with a diagnosis of NAFLD as either a primary or secondary diagnosis are 
include in the black bars, with the total number of patients are included in the grey bars. 
Data courtesy of Elisa Allen at NHSBT. 
As a proportion of all elective cases on the liver transplant waiting list those with NAFLD as a 
primary/contributory factor still account for a relatively small amount. This may reflect a 
low number of patients with end-stage liver disease due to NAFLD or challenges with 
identifying/referring and listing such patients for transplantation. Further exploration of 
these data are required to ensure equity of access to transplantation for such patients, 
although the likely higher presence of co-morbidities is a relevant consideration. 
 
Metric 6.5: Number of bariatric surgery operations per 100,000 population 
This metric is a measure of the extent of service provision for those in clear need of further 
support and intervention. Referral to weight management services and consideration of 
bariatric intervention is strongly supported by an evidence base. 
The current rate of service provision is much less than 1% of those with a BMI ≥40 kg/m2 
and more recent data from the Health and Social Services Information Centre indicate an 
almost 10% fall in the number of NHS bariatric surgery procedures (Figure 14). Notably, the 
rate of surgery in Sweden which is a similar European country was 78 procedures per 
100,000 population in 2013 (data from Scandinavian Obesity Surgery Register(77)). This 
would equate to a figure of 49,000 procedures per annum for the UK which is >6 times the 
current rate of service provision. There is no justification for such a difference, especially 
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when the higher rate of obesity in the UK is taken into account, testifying to the marked 
under-provision of bariatric surgery in the United Kingdom. 
Figure 14: Hospital Episode Statistics (HES) data on FCE for patients admitted for bariatric 
surgery. 
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Recommendation 7:    Eradication of chronic HCV infection from the country 
by 2030 and a major reduction in the burden of disease for hepatitis B 
  
Panel 9:  Metrics for Recommendation 7 
7.1: Number of HCV infected patients treated with new HCV DAAs and number of 
patients achieving cure / SVR12. 
7.2: Number of patients diagnosed with HCV and HBV        
7.3: Mortality from HCV and HBV -  number of HCV or HBV associated HCC’s, 
number of transplants for HCV or HBV and HES data for bed days associated 
with HCV and HBV infection              
7.4: Numbers of infants starting and numbers completing a course of HBV 
vaccination 
7.5: Universal HBV vaccination offered by region – yes / no    
 
The Lancet Commission on Addressing Liver Disease in the UK from 2014(11) made a number 
of key recommendation for viral hepatitis – including eradication of infections from chronic 
hepatitis C virus in the UK by 2030 using antiviral drugs; reducing the burden of hepatitis B 
virus; target high-risk groups for these viruses, including immigrant communities; use of a 
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universal six-in-one vaccination for infants for hepatitis B. This report looks at metrics to 
measure progress towards these goals.  
In May 2016, 194 governments, including the UK, adopted the WHO’s first ever Global 
Health Sector Strategy for Viral Hepatitis (GHSS) at the 69th annual World Health Assembly. 
The strategy sets a goal of eliminating hepatitis B and C by 2030 and includes prevention 
and treatment targets(78).  
The metrics shown in Panel 9 were selected to align both with the Lancet Commission’s 
recommendation and the GHSS.  The first 4 link with the 10 core indicators for monitoring 
and evaluating HBV and HCV infection recommended in a recent WHO document 
(Monitoring and Evaluation for viral hepatitis B and C: recommended indicators and 
framework) and will facilitate comparisons with other countries and allow year by year 
monitoring of  progress made. According to the WHO report the 10 core indicators are 1) 
prevalence, 2) infrastructure for testing, 3) vaccination coverage of newborns for HBV, 4) 
needle – syringe distribution, 5) facility level injection safety, 6) people diagnosed, 7) 
treatment coverage/ initiation, 8) HCV cure and HBV suppression numbers, 9) incidence of 
new infection, 10) attributable mortality and morbidity. 
 
Metric 7.1:  Number of HCV infected patients treated with new HCV DAAs and number of 
patients achieving cure / SVR12 (links with WHO 8) 
 - allows a direct comparison of numbers cured with numbers of newly diagnosed HCV 
infections as an indicator of progress towards eradication and reduction in prevalence   
 - allows comparison of treatment numbers with other in other European countries and the 
impact of any initiatives for testing and treating HCV 
Treatment numbers in the UK are rising. As of 22 August 2016, in England 3482 patients 
with HCV have been initiated on treatment since 1st April (2.2% of the estimated 160,000 
chronically infected cases [81], with a target of 10,000 to be treated by the end of March 
2017 (6.3% of the prevalent population). The present focus of NHS England is on patients 
with advanced liver disease and plans to increase the proportion of patients on therapy year 
on year are dependent on an anticipated fall in drug costs as a consequence of increased 
competition. Despite the rise in therapy, eradication of HCV in England by 2030 is 
unachievable with these numbers as it will take until 2032 to treat the known patient pool, 
without treating any new infections, and either a marked increase in funding or a reduction 
in the cost of treatment will be needed to achieve the goal of eradication. There are no new 
widespread testing programmes in place in England currently to increase diagnosis.  
In Scotland in 2015, 1700 patients with HCV were treated with similar numbers expected for 
2016. This represents about 4.5% of the estimated 38,000 chronically infected cases (data 
from John Dillon). In Wales, central funding was provided from 2015/16 with 464 patients 
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treated and funding to treat 900 in 2016/17 (data from Brendan Healy). This represents 
7.5% of the estimated 12,000 chronically infected cases.  
By comparison, in Australia (where the price of therapy is capped to allow unlimited access) 
22,470 individuals were started on treatment from March to June 2016, close to 10% of the 
total infected population of 230,000 in just 4 months (The Kirby Institute. Monitoring 
hepatitis C treatment uptake in Australia (Issue 4)(79). In Germany (where expenditure on 
antiviral drugs is estimated to be five times greater than in England) treatment numbers are 
estimated to be stable at 25,000 per year since 2015, 10% annually of their estimated 
prevalent pool of 250,000(80).  In Australia and Germany all of the known diagnosed HCV 
cases will be treated within a few years and there are plans for widespread testing 
programmes to diagnose the remaining cases.  
Figure 15:  UK Treatment numbers – from Hepatitis C in the UK – annual report 2016(81)  
 
Sustained viral response (SVR)  rates for treatment initiated in the current year are not yet 
known but the earlier NHS England Early Access Programme for advanced liver disease 
which treated 467 patients (409 with decompensated cirrhossi) achieved an overall SVR rate 
of 81.6% (381/467). For genotype 1 infection SVR was 90.5% (209/231) and 68.8% for 
genotype 3 (132/192)[78]. 
Note to the editor:  Gaps: SVR data for NHS E treated cases – we should have SVR 12 data 
for patients treated between April and June/July before publication in December. 
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Metric 7.2:    Number of patients diagnosed with HCV and HBV (ties in with WHO 2 and 6) 
 In England and Wales there were 11,626 laboratory reports of newly diagnosed HCV 
infection in 2015 (11,997 in 2014). Some of these will be recent infections and others 
previously undiagnosed long standing chronic HCV. This is greater than the number of 
patients being treated. 
Table 8:  Laboratory reports of hepatitis C by region, England and Wales (2006-2015) – from 
Laboratory reports of hepatitis A infection, and hepatitis C: 2015, PHE 
 
PHE Centre                                                                                              Year  
 
 
2006  
 
2007  
 
2008  
 
2009  
 
2010  
 
2011  
 
2012  
 
2013  
 
2014  
 
2015  
 
East 
Midlands  
259  402  588  576  515  673  672  549  591  401   
East of 
England  
684  695  794  706  607  844  776  707  792  840   
London  1190  1017  966  856  968  2012  2789  3089  3836  4091   
North 
East  
245  141  167  275  317  310  301  360  305  233   
North 
West  
1380  1737  1666  2117  1807  1514  1797  1981  1496  1385   
South 
East  
379  786  1083  1147  1170  1300  1298  1137  1323  1331   
South 
West  
872  1046  1114  999  732  973  1111  997  983  1077   
West 
Midlands  
487  614  673  860  778  774  740  781  648  864   
Yorkshire 
and 
Humber  
1449  1363  1344  1091  981  1507  1376  1470  1513  1326   
Wales  327  333  487  356  318  486  502  690  510  78   
Total  7,272  8,134  8,882  8,983  8,193  10,393  11,362  11,761  11,997  11,626**   
 
Nearly all new cases of HCV infection arise in injection drug users with incidence remaining 
relatively stable at 8/100 person years in 2015 and 7/100 person years in 2011. The 
prevalence of HCV in injection drug users also shows no sign of reducing with around 25% of 
injection drug users being HCV antibody positive within 3 years of first injecting –see figure: 
Figure 16: Estimated UK-wide prevalence of antibodies to hepatitis C among people who 
began injecting drugs in the previous three years, 2008-2015.* 
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For 2015, a total of 457 cases of acute/probable acute HBV infection were reported – an 
annual incidence of 0.83/100,000 population/year (Acute hepatitis B(England): annual 
report for 2015 – PHE(8). 
 
Metric 7.3: Mortality from HCV and HBV -  number of HCV or HBV associated HCC’s, 
number of transplants for HCV or HBV and HES data for bed days associated with HCV and 
HBV infection (WHO 10) 
The PHE annual report on Hepatitis C in the UK for 2016 presents a new evaluation of HES 
data that allows estimation of the number of new cases of end stage liver disease or 
hepatocellular carcinoma arising as a consequence of HCV infection. There are some 
limitations due to variations in datasets between UK countries. However, these show a fairly 
constant number of approx. 1800 new cases each year since 2010 
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Figure 17: Preliminary estimates of incidence* of HCV-related ESLD**/HCC in the UK: 2010-
2015 
  
 
Between 2005 and 2014, deaths annually from HCV-related ESLD and HCC in the UK rose 
from 215 to 457. Although 2015 data are preliminary and should be interpreted with 
caution, it is encouraging to see an observed fall in mortality of 11%. It is possible that this 
fall is the result of new DAA drugs introduced from 2014/2015, particularly for those 
individuals with advanced disease. 
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Figure 18: Deaths from ESLD* or HCC in those with hepatitis C mentioned on the death 
certificate in the UK: 2005 to 2015 
 
In the year to March 2015, 119 (19% of total) HCV infected adult patients underwent an 
elective liver transplant, in 2014 the figure was 133 (21%). 
Note to editor: data for HBV from HES data is due to be published and will be available for 
insertion into paper before publication      
 
Metric 7.4: Numbers of infants starting and numbers completing a course of HBV 
vaccination (WHO 3) 
Public Health England reports vaccine coverage data in England for three doses of hepatitis 
B vaccine in infants born to hepatitis B surface antigen (HBsAg) positive mothers who 
reached the age of one year in this quarter (i.e. those born between January to March 
2015), and coverage of four doses of vaccine in infants who reached two years of age (i.e. 
those born between January to March 2014). The 2015-15 data shows 86% vaccine 
completion (1699/1987 infants) at 12 months and 74% completion (1681/2275) at 24 
months. For the first quarter of 2016, the 12 and 24 month returns (data from 127 and 122 
of 151 former PCTs respectively) shows 91% of 481 infants received 3 doses of vaccine by 12 
months and 69% of 495 infants received all 4 doses by 24 months. 
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Metric 7.5:  Has Universal vaccination for HBV been introduced – yes / no  
At the time of writing, the Government has accepted universal immunisation for hepatitis B 
but this has not been introduced. 
 
Recommendation 8:  Increasing awareness of liver disease in the general 
population, within the NHS and, vitally, with governments. Increasing the 
inclusion and involvement of liver patients and patient groups in new 
developments and on-going work with national and local initiatives. 
 
Panel 10:  Metrics for Recommendation 8:   
1. Government Supported National Liver Plans  
2. Regional variation in PHE health profiles 
3. Inclusion and involvement of patient and patient support groups 
4. PH sponsored campaigns in obesity and alcohol 
 
Metric 8.1: Government Supported National Liver Plans 
The initial Lancet Commission on Liver Disease’s report highlighted that the increasing 
burden of liver disease in the UK was getting worse and that currently liver disease is the 
third most common cause of premature death and the trajectory has been a 400% increase 
since 1970 and that trajectory continues to climb ever higher. In order to decrease this and 
improve the care, treatment and support those with and affected by liver disease receive 
National Liver Plans have got to be developed to clearly outline government supported 
actions and improvements for liver health right from prevention through to cure, long term 
support and end of life care include all liver health issues for children and adults. To support 
the Plan a multidisciplinary implementation committee, with patient representation, needs 
to be formed to deliver and monitor their success. In addition to support the clinical 
elements of the Plan’s recommendations a National Clinical Director for Liver Health needs 
to be appointed to lead on the improvements needed. The current situation is outlined in 
the table below. 
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Table 9:  Introduction of National Liver Plans  
 ENGLAND NORTHERN 
IRELAND 
SCOTLAND WALES 
National Liver 
Plan 
No published 
plan 
No published 
plan 
No published 
plan 
Together for Health 
– Liver Disease 
Delivery Plan (May 
2015) 
http://bit.ly/1QlsFbY 
 
Implementation 
Committee 
No published 
plan 
No published 
plan 
No published 
plan 
Developed with 
patient 
representation 
National Clinical 
Director 
No published 
plan 
No published 
plan 
No published 
plan 
Dr Andrew Yeoman 
appointed 2016 
 
The value and impact of the work on the Welsh Liver Plan’s recommendations is already 
having a positive effect in Wales and provides a benchmark for what the other countries 
need to develop. 
Metric 8.2:  Geographical variation in Liver Disease Mortality: Public Health England Local 
Authority Liver Disease Profiles 
Variations in mortality rate from liver disease persist between Local Authorities in England 
with a fourfold variation in mortality rates for males and females - variation is 3.8 for males 
(Blackpool rate 52 per 100,000 compared to Buckinghamshire rate 13.7), variation 4.3 for 
females (Blackpool rate 28 compared to rate of 6.6 for Barnet) . The variation is even more 
stark when years of life lost under 75’s are compared, with an eight fold variation - variation 
is 8.4 (Blackpool 89.3 YLL per 10,000 compared to Rutland 10.5). These variations reflect 
both variation in risk factors but also variation in access to NHS Services. PHE will publish an 
updated Atlas of Variation in Liver Disease. 
The commission recommends that all countries develop local liver health profiles and use 
them to address inequalities and prioritise improvements with annual updates to evaluate 
success 
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Table 10:  Introduction of Local Liver Health profiles across devolved countries 
 ENGLAND NORTHERN 
IRELAND 
SCOTLAND WALES 
Local Liver 
Health Profiles 
http://bit.ly/ZY2i6y Not done yet Not done yet Not done yet 
 
Metric 8.3: Inclusion and involvement of patient and patient support groups 
In order to best address the holistic needs of patients it is vital to have their involvement 
and input into new developments, service design, on-going governance etc. There is still a 
need to ensure this happens and all health officials and clinicians need to advocate for this 
when it is not present. In the Liver QuEST(52) project to support the improvement of 
hospital liver services, the  peer review teams include patients but so far, as described 
earlier, only a small number of DGHs have been visited. 
It should also be noted that in England there has also been the development of 22 Hepatitis 
C Operational Delivery Networks with the aim of 100% patient involvement as soon as 
possible with the help and support of the Hepatitis C Trust, to date this has not been 
audited but will be before the next Lancet liver commission update. 
 
Metric 8.4:  PH sponsored public awareness campaigns for obesity and alcohol 
To inform and raise public awareness, campaigns about the two main causes of liver 
disease, alcohol and obesity, need to be developed and further promoted effectively to 
ensure the public is as informed as possible and people are empowered to make beneficial 
improvements to their lifestyle. Ongoing and frequently updated national campaigns are 
vital to reverse the increasing burden of preventable liver disease.  
Examples of government funded national campaigns are in the table below, in addition 
many charities, including Alcohol Concern, CRUK, Diabetes UK and the British Liver Trust, 
have national campaigns that highlight the detrimental effects obesity and alcohol have on 
our health. 
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Table 11:  National awareness campaigns 
 ENGLAND NORTHERN 
IRELAND 
SCOTLAND WALES 
National 
obesity 
campaign 
Change for Life 
http://bit.ly/1eC1
t78 
One You  
http://bit.ly/24Lf
OIf 
 
Choose to live 
better 
http://bit.ly/1Q0f5
yC 
 
Let's Make Scotland 
More Active 
http://bit.ly/2bik2A
Y 
Take Life On 
http://bit.ly/2bik2A
Y 
 
Health Challenge 
Wales – obesity 
http://bit.ly/2aAkVYu 
  
National 
alcohol 
campaign 
Change for Life 
http://bit.ly/1eC1
t78 
One You  
http://bit.ly/24Lf
OIf 
Know Your Limits 
http://bit.ly/2aL3q
pZ 
Alcohol Behaviour 
Change campaign 
http://bit.ly/2aAgEn
U 
Health Challenge 
Wales – alcohol 
http://bit.ly/2belAwQ 
 
 
 
General Policy Strategy in the Devolved Nations 
 
1. Scotland 
 
Professor John Dillon writes that liver disease in Scotland as in the UK is driven by alcohol, 
obesity and hepatitis C with all three being more prevalent in Scotland than the rest of the 
UK. As in the rest of the UK the natural history of liver disease is of late presentation with 
decompensated liver disease or hepatocellular carcinoma, with a pressing need to develop 
strategies for earlier detection and more effective intervention. Scotland does not have an 
integrated liver plan but has a series of activities that cover the major causes and 
management of liver disease. These include an “Alcohol strategy”, “the sexual health and 
blood borne virus frame work” and a department of health initiative to improve out-
patients, the “National Delivering Outpatient Integration Together (DO IT) Programme” with 
a work stream focussed on abnormal LFTs. 
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Figure 19:  
 
 
The current Scottish alcohol strategy is undergoing a review, this is not planned to be a 
whole new strategy but an opportunity to add to and adjust the existing policies in the light 
of experience with the strategy.  Scottish Health Action on Alcohol Problems (SHAAP) with 
the support of Scottish Government has brought together a working group that has 
produced recommendations for a focus with in the strategy on alcohol related liver disease, 
as this is a major driver for mortality and costs, the major recommendations are for an 
assessment of liver fibrosis in all those presenting with alcohol excess and a prioritisation for 
alcohol treatment in those with evidence of advancing fibrosis. It will further recommend 
that those admitted to hospital with the consequences of alcohol related liver disease 
receiving high quality standardised management in accordance with the BSG/BASL care 
bundle and that they are in contact with alcohol services prior to discharge with effective 
follow-up treatment plans in place. How these interventions are delivered either with in-
reach from existing alcohol treatment services or the development of formal alcohol teams, 
as developed in other parts of the UK, is under consideration. 
The policy planks of the existing alcohol strategy have had significant impacts on reducing 
alcohol related mortality. In 2015, there were 1,150 directly related alcohol deaths, (this 
definition is largely driven by alcohol related liver disease), the third lowest annual total 
since 1997, compared to the peak of 1,546 in 2006 (Figure 20) it is speculated that the fall is 
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secondary to the increases in the price of alcohol due to the economic down turn and 
policies banning alcohol multi-buy promotions, which were not subject of legal challenge. It 
provides further in-direct evidence that price is a key lever for change in alcohol related 
mortality. Minimum Unit Pricing could have an even greater impact, however it remains 
under a prolonged process of judiciary review, but the government is still committed to its 
implementation.   
At the World Hepatitis summit the Scottish Government signed the Glasgow Declaration 
committing to the elimination of HCV, it remains committed to removing HCV as a 
significant public health issue in Scotland. They have committed to achieving sufficient 
patients diagnosed and treated to reduce HCV related liver failure and HCC by 75% by 2020 
form 2015 levels. HCV treatment targets have been exceeded, even with a focus on treating 
those with most fibrosis first, this combined with increased HCV prevention activity has seen 
year on year falls in the prevalence of HCV. There is also early evidence of a fall in the 
numbers of patients presenting with HCV related liver failure.  
The management of abnormal LFTs continues to be a major challenge with many not being 
investigated and only 1.4% converting into a liver diagnosis in some series. The liver work 
stream of the “DOIT” program is focussed on the management of abnormal liver function 
tests, ensuring all with significant liver disease are investigated, while limiting the impact on 
hepatology services from non-significant abnormality of LFTs. A pilot project currently 
nearing completion is using a minimal set of diagnostic criteria for liver diseases combined 
with automatic cascading of “liver screen” investigations on the original sample when first 
discovered to be abnormal. In preliminary results the process is assigning a liver diagnosis to 
over 50% of patients based just on the liver screen and aetiological information. While the 
full results of the pilot are awaited “DOIT” has started planning for implementation of this 
diagnostic pathway. 
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Figure 20: Alcohol-related deaths registered in Scotland, 1979 to 2015, with five-year moving 
average, and showing the likely range of values around the moving average. Definition of 
alcohol-related deaths as used by the Office for National Statistics in 2006. (82).   
 
2.  Wales 
Dr Andrew Yeoman has written as follows:  In 2015 the Welsh Government launched a 
national strategy, the “Together for Health: Liver Disease Delivery Plan”, as a means of 
tackling the rise in morbidity and mortality related to liver disease observed in Wales which 
has mirrored that seen across the United Kingdom. The publication of the plan was the 
culmination of a collaboration between Public Health Wales and the Welsh Association of 
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Gastroenterology and Endoscopy (WAGE) and involved consultation with key stakeholders. 
In late 2015 an implementation group was convened to oversee delivery of the plan and to 
identify appropriate ways to invest the £1 million per year allocated to the plan by Welsh 
Government.   
 
The plan aims to improve activity across six key areas: Prevention, Early Detection, Fast and 
Effective Care, Living with Liver Disease, Improving Information and Targeting Research. 
Each of these has major objectives and metrics associated with them. The implementation 
group has supported the development of specific sub-groups with defined remits and those 
formed to date include the blood borne virus sub-group as well as early detection and 
clinical services subgroups. Recently, a national clinical lead (0.2 whole time equivalent) has 
been appointed and a full time administrator is soon to be appointed to support the delivery 
of objectives determined by the implementation group. 
 
Although still in the relatively early stages of the plan, there have been areas of significant 
progress in relation to the care of patients with liver disease in Wales. First among these is 
undoubtedly the work of the Wales blood borne virus network. This network consists of 
representatives from each of the 6 Health Boards in Wales as well as an external advisor, 
Professor David Mutimer from the Birmingham Liver Unit. Criteria (Fibroscan >9.5kPa or 
other urgent need for therapy) were set and patients were discussed by panel for 
appropriateness if discordant or extenuating circumstances were apparent. This 
collaborative has therefore ensured equitable access to new therapies across the whole of 
Wales and has been supported by an excellent, established network of specialist nurses.  
 
This approach was supported by central government funding and, for the financial year 
2015-2016, delivered directly active anti-viral therapy to 464 patients in Wales, mainly with 
cirrhosis or advanced fibrosis. For 2016-2017 further negotiated funding has been agreed to 
treat approximately 900 patients and the access criteria relaxed (Fibroscan 6kPa). 
Importantly, treatment of this number of individuals on a recurrent basis should lead to a 
reduction in the population prevalence of the disease. 
 
The success to the network is also evident in the development of a series of industry 
partnerships which has led to specific initiatives around improving detection and provision 
of treatment too difficult to challenging groups such as prisoners or injecting drug users. 
Five of the six Welsh treatment centres are involved in these initiatives as pilot sites with 
the learning to be shared across Wales. 
 
Also in the field of viral hepatitis, funding agreed through the liver plan has been awarded to 
modify the Wales Harm Reduction Database to include a comprehensive blood borne virus 
module.  The module will cover the initial screening, consent and testing, diagnosis and 
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referral to specialist treatment services for hepatitis B, hepatitis C and HIV.  It is expected 
that the module will be fully implemented, following training across Wales, early in 2017. A 
blood borne virus specific electronic clinical management system is also in development. 
 
Liver plan funding has also been allocated to developing point of care testing in viral 
hepatitis that does not rely on venous samples or dried blood spot tests being sent to a 
laboratory, thus streamlining the pathway.  
 
Outside of viral hepatitis, a key early priority identified in relation to liver disease in Wales 
was the support for the development lack of secondary care based alcohol care teams. Prior 
to support from the liver plan such services were extremely patchy nd in some Health 
Boards non-existent.  The plan has supported clinicians in Health Boards to develop their 
own regional plans for alcohol care teams including ensuring alcohol misuse becomes an 
organisational priority in their Integrated Medium Term Plans. To start this process the liver 
plan has allocated £1 million of funding over a 2 year period to “pump prime” the ongoing 
development of alcohol care teams in each Health Board in Wales. To date, 4 Health Boards 
have had funding approved for this purpose with the remaining 2 plans being in an 
advanced stage of development. 
 
In regards the early diagnosis of liver disease and to improve links with primary care, a pilot 
is currently running in one Health Board to ascertain the utility of “reflexly” measuring the 
AST when an ALT is found to be elevated so enabling calculation of the AST/ALT ratio which 
was supported in the first iteration of the Lancet commission as having the potential to 
earlier identify those with advanced fibrosis or cirrhosis and so those with a ration of >1 are 
referred for further assessment.  
  
Given that the majority of patients with cirrhosis are diagnosed at the time of an admission 
with decompensation, it is hoped that not only will this work lead to an earlier diagnosis of 
cirrhosis but avoid the need for the patient to return for a second blood test. In addition this 
approach has the potential to not only reduce GP workload (via reduced patient recall) but 
re-inforce the knowledge that minimal elevations of ALT can be associated with serious 
disease.  
 
This work will also feed into the planned development of an all Wales pathway for the 
management of abnormal liver function tests. In this regard, a dedicated Hepatology away-
day (including contributions from several Lancet Commissioners), is taking place in October 
2016 and has a strong focus on pathway development.  
 
Other work currently being developed is a collaboration to improve public and patient 
knowledge of the risks of and care of liver disease, as well as the development of mature 
60 
 
patient and carer support groups across the whole of Wales. An opportunity is also being 
explored with fledgling wellness services to link the lifestyle factors recorded in such 
consultations with risks of liver disease. Finally, work is being undertaken to improve access 
to liver transplantation for patient in Wales via the establishment of stronger regional 
networks and outreach clinics with transplant physicians.  
 
Hence, whilst much remains to be done to tackle the burden of liver disease in Wales, there 
is firm political support and an increasing body of multi-disciplinary professionals with the 
commitment to do so.  
 
3. Northern Ireland 
Dr Neill McDougall, Clinical Lead for Hepatology in Northern Ireland, has written as follows:   
Northern Ireland is well behind England with respect to screening for early liver disease in 
the community, partly due to the different structures.  I am due to meet one of our 
commissioners in next few weeks regarding the two recent NICE guidances (NAFLD and 
diagnosing cirrhosis) but we are nowhere near implementation.  Also we have not fully 
implemented the NICE guidance on hepatitis B (due to resource implications for Fibroscans). 
 
With respect to provision of services (Recommendation 3) Northern Ireland has a single 
regional liver unit in Belfast.  NO OTHER hospitals have >2 hepatologists although most of 
the 9 hospitals outside Belfast have one gastroenterologist with a liver interest.  This has 
been a definite improvement over the past 5yrs due to recent appointments.   
 
In relation to specialist paediatric services and continuity of care in transition to adult 
services, Northern Ireland is currently well served by the special arrangement it has with 
Kings College Hospital, functioning as an outreach centre.  There are weekly meetings via 
video conference to the Kings OLT listing meeting, a joint Kings-Belfast clinic every 2 months 
and Northern Ireland is the single biggest referrer of patients to Kings.  The last UK data 
from 2015 showed the highest number of patients listed per head of population (if you 
exclude Isle of Man) although numbers transplanted fell back into the main stream, with 20-
24 transplants per year.  Survival data on 255 patients transplanted up to 2012 (90.9% 1yr 
survival, 80.2% 5yr survival, EASL 2014) showed that shared care arrangement deliver 
outstanding results.  
 
Paediatric liver transplant work is done through Birmingham (historical arrangement).  And 
there is a very good transition arrangement with the hepatologists from Birmingham and we 
join them in seeing adolescent patients over 1-2yrs at the paediatric clinic before they 
transition to the adult transplant service for follow-up. 
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On alcohol care services Northern Ireland is making excellent progress and the Chief 
Medical Officer, Dr Michael McBride, has been a strong supporter of this work. Data on the 
number of specialist nurses and Alcohol Care Teams is covered in Recommendations 2 and 
5. Dr Roger McCorry, who leads the Belfast Trust Alcohol Care Team, reports that very 
recently THREE consultant led Alcohol Care Teams have been established in Northern 
Ireland, one in Belfast and in 2 of the other 4 Trusts.  A regional alcohol care-pathway has 
also recently been completed with a view to standardising alcohol screening and care across 
the province. 
 
Northern Ireland has an excellent HCV treatment programme which is able to provide all 
NICE approved treatments for NI patients.  There is a single virology laboratory so that all 
results go through one centre and all treatment is delivered through the Regional Liver Unit 
in Belfast.  There is also a Hepatitis Network for NI – a collaborative effort between Public 
Health and ourselves that helps to address the wide range of issues with viral hepatitis 
including screening, prevention, treatment pathways etc.   
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